

ACCELERATING DIABETES CARE **FOR LIFE**



American
Diabetes
Association.

Overcoming
**Therapeutic
Inertia**

ARLINGTON, VA • NOVEMBER 28, 2018

Clinical Inertia in Diabetes – Research



Swapnil Rajpathak MD DrPH

*Executive Director for the Center for Observational and
Real World Evidence*

Merck

Kenilworth, New Jersey




Overcoming
**Therapeutic
Inertia**

Research studies in clinical inertia

Demonstrate prevalence

Median time to receive additional antihyperglycemic medication is more than 1 year among those failing metformin monotherapy (DOM 2011)




Impact of inertia on glycemic goal attainment

GE/Quintiles EMR study (JDC 2014): Earlier intensification helps more patients achieve glycemic goals

Local data generation

Countries replicating findings from global studies

External Collaborations



30-40% patients who may be appropriate for an add-on to metformin based on clinical guidelines are not intensified

Ongoing studies



- ✓ Impact of inertia on clinical and economic (healthcare utilization and costs) outcomes
- ✓ 2018 ADA abstract



- ✓ Development of EMR based tool to reduce inertia
- ✓ Planned for submission ADA 2019